Overall Survival with Inavolisib in <i>PIK3CA</i> -Mutated Advanced Breast Cancer

Komal Jhaveri(Memorial Sloan Kettering Cancer Center), Nicholas C. Turner(Institute of Cancer Research), Thomas J. Stout(Exelixis (United States)), Noopur Shankar(Cancer Research Institute), Seock‐Ah Im(Seoul National University), Sibylle Loibl(Goethe University Frankfurt), Cristina Saura(Vall d'Hebron Hospital Universitari), Ted Clark, Dejan Juric(Massachusetts General Hospital), Chunyan Song(Zhengzhou Central Hospital), Yanling Jin(Roche (Canada)), Eirini Thanopoulou(Cancer Research Institute), Sherene Loi(The University of Melbourne), Peter Schmid(Queen Mary University of London), Kevin Kalinsky(Emory University)
New England Journal of Medicine
May 31, 2025
10.1056/nejmoa2501796
Cited by 79

Related Papers

Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k